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Abstract 
This study was conducted to determine the feasibility of detecting BRAF(V600E) 
circulating tumor DNA (ctDNA) in the plasma of patients with thyroid nodules, with the 
goal of distinguishing between benign and malignant nodules. Plasma samples from 
patients undergoing thyroid surgery for thyroid nodules were obtained prospectively pre-
operatively and one month post-operatively, and quantitative-PCR was used determine 
the presence of BRAF(V600E) ctDNA. These were compared to formalin fixed paraffin 
embedded samples from the index nodule. Thirty-eight pairs of preoperative and 
postoperative plasma samples were collected and analyzed. 6/18 (33.3%) patients with 
classical PTC and 0/8 (0%) patients with nodular hyperplasia had detectable levels of 
BRAF(V600E) ctDNA  pre-operatively, thus BRAF(V600E) ctDNA was able to 
distinguish between benign and malignant nodules (p < 0.05).  The levels of all samples 
with detectable BRAF(V600E) ctDNA pre-operatively declined post-operatively (p < 
0.05). BRAF(V600E) ctDNA can be detected in plasma. Post-operative drop of 
BRAF(V600E) ctDNA in all cases suggests its utility as a tumor marker. 
Keywords 
Circulating tumor DNA, cell free DNA, ctDNA, thyroid cancer, thyroid nodule, 
BRAF(V600E) 
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1.     Introduction 
 
There is an increasing incidence of thyroid cancer in developed countries, with 
approximately 75% of these cases occurring in women. Although approximately 50% of 
thyroid glands have thyroid nodules when examined at autopsy, during surgery or by 
ultrasound, approximately two-thirds of these are benign.1 Up to 35% of thyroid glands 
removed at autopsy or surgically have clinically unimportant thyroid cancers, primarily 
papillary thyroid cancers (PTC) less than 1.0 cm.2,3 It is the most common endocrine 
malignancy worldwide and tenth most common cancer in Canada.4 In Canada, from 1986 
to 2010, the age standardized incidence rate (ASIR) for thyroid cancer increased from 2.0 
to 5.9 per 100,000 in males and from 5.2 to 20.6 per 100,000 in females (Figure 1).5 
There was a 6.3% per year increase in incidence of thyroid cancer in males from 2001 to 
2010 and 4.4% per year increase in incidence of thyroid cancer in females from 2005 – 
2010.  
 
In the U.S. there has been a steady rise in the rate of primary thyroid malignancies with 
37,200 new cases diagnosed in 2009, 48,000 new cases diagnosed in 2011 and 
approximately 60,220 new cases diagnosed in 2013.6-9 There has been increased 
utilization of fine needle aspirate biopsies (FNAB) in managing these thyroid nodules and 
in 2011 an estimated 450,000 thyroid fine needle aspirate biopsies (FNABs) were 
performed.9,10 Increased incidence of thyroid cancer has been largely attributed to 
increased use of ultrasound which can detect sub-centimeter thyroid nodules and routine 
use of FNAB as first line replacing nuclear medicine scans.4,10,11 The majority of these 
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new case are very early stage disease, with 68% being T1 cancers of 2.0 cm or less (39% 
less than 1.0 cm and 29% between 1.0 to 2 cm).6,10,12 Other hypotheses for this dramatic 
rise in incidence include increased exposure to medical radiation, increased dietary iodine 
intake, and increased prevalence of chronic autoimmune thyroiditis.4,11  Despite the 
increasing incidence of thyroid cancer, mortality rates have not changed over the past 
decade, implying that the majority of these newly identified cases are low risk disease.6,10  
Thyroid neoplasms include thyroid adenoma, well differentiated thyroid cancer, poorly 
differentiated thyroid cancer, anaplastic (undifferentiated) thyroid cancer and medullary 
cancer (Figure 2)13. Well differentiated thyroid cancer is by far the most common type of 
thyroid cancer with PTC being the most common in about 85% of the cases, follicular 
thyroid cancer (FTC) in about 10% of the cases and finally Hurthle cell or oxyphil tumors 
in 3% of the cases (Table 1).14,15 
 
1.1 Contemporary Thyroid Nodule Management 
 
According to American Thyroid Association guideline, a detailed history and physical is 
the first step in evaluating a patient presenting with thyroid nodule (Figure 3).16 Risk 
factors for thyroid cancer include family history of thyroid cancer in one or more first 
degree relatives, certain thyroid cancer syndromes (e.g. Cowden’s syndrome, Familial 
Polyposis, Carney Complex, Multiple Endocrine Neoplasia 2, Werner syndrome) in first 
degree relative, and previous exposure of neck to ionizing radiation. Thyroid Stimulating 
Hormone (TSH) levels should be measured, and in patients with low TSH, a radioactive 
iodine scan should be done to assess for a hyper-functioning nodule. Patients with hyper-
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functioning nodules are very unlikely to have a thyroid cancer (~1%). If the patient has a 
normal or high TSH, ultrasound assessment of the thyroid bed is essential to measure the 
nodule size and characteristics. Although no single sonographic feature or combination of 
features is highly specific or sensitive in diagnosing nodules to be malignant, certain 
ultrasound characteristics, such as microcalcifications, hypoechogenicity compared to the 
thyroid bed, increased nodular vascularity, infiltrative margins (absent halo) or taller than 
wide on transverse view, can be helpful in identifying high risk nodules.17-22 In contrast, 
spongiform and purely cystic nodules are likely to be benign nodules.18,23 Ultrasound is 
also helpful in assessing the presence of any cervical lymphadenopathy in the setting of 
thyroid cancer, as it identifies suspicious cervical lymphadenopathy in 20 – 31% of the 
cases.24-27 For those patients who do not fall into the high risk category, thyroid nodules 
greater than 1 cm or those which are increasing in size (20% increase in nodule diameter 
with a minimum increase in two or more dimensions of at least 2 mm or 50% increase in 
nodule volume) should be biopsied with a fine needle aspirate biopsy (FNAB).16,28-30 
Nodules that are greater than 4 cm should be removed surgically, as the diagnostic 
sensitivity decreases with increasing size.31 
  
FNAB reports are based on the Bethesda system, where the FNAB specimen is assessed 
by a cytopathologist and the likelihood of malignancy is reported. The results are divided 
into 5 categories (Table 2).32 As evident from the malignancy risk, FNAB is extremely 
useful for the low and high risk categories, but it does poorly in the 
indeterminate/intermediate category. Thus, patients may undergo diagnostic hemi-
thyroidectomy, surveillance ultrasounds and FNAB, which results in significant patient 
discomfort and increased cost to the health care system. 
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1.2 Risks of Thyroid Surgery 
 
As previously noted, diagnostic hemi-thyroidectomy is recommended for those with 
FNAB reported as indeterminate/intermediate risk of cancer. Thyroid surgery is 
associated with the risks of general anesthetic, bleeding, infection, transient or permanent 
hypothyroidism, transient or permanent hypocalcemia (if total thyroidectomy), and injury 
to both superior and recurrent laryngeal nerve resulting in voice alteration, dysphagia and 
potential airway compromise. Injury to the superior laryngeal nerve can result in inability 
to raise the pitch of the voice and altered sensation of the hemi-larynx. Recurrent 
laryngeal injury is more severe, as it results in a paralyzed vocal cord on the affected side, 
thus resulting in a breathy voice.  The overall incidence of this complication is 2 – 
10%.33,34 Although the risks are generally lower in the hands of high volume thyroid 
surgeons, 50% of thyroid surgeries in the U.S. are performed by low volume surgeons 
who do less than 5 thyroidectomies per year.35  
 
Thus, by improving the accuracy of diagnosis and decreasing the risk of malignancy in 
the indeterminate/intermediate category of FNAB, diagnostic surgeries can be avoided. 
This has the potential to decrease costs in an already strained Canadian healthcare 
system.   
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1.3 Thyroid Cancer Follow up 
 
Currently thyroid cancer surveillance is done by stimulated and unstimulated 
thyroglobulin levels and radioactive I131 scan in select cases that receive adjuvant 
radioactive iodine.16 Twenty-three to 29% of patients with well differentiated thyroid 
cancers have antithyroglobulin antibodies, thus making surveillance of thyroid cancer 
recurrence difficult.36-39 Moreover, 12% of cases are thyroglobulin negative                 
pre-operatively with the entire gland in situ, highlighting the imperfections of 
thyroglobulin for monitoring disease burden.40  Thus a new test that can aid in thyroid 
cancer surveillance would be highly beneficial. 
 
1.4 Genetics of Thyroid Cancer 
 
Three distinct pathways are proposed for neoplastic transformation and proliferation of 
thyroid follicular cells: hyper-functioning follicular thyroid adenoma, FTC and PTC (see  
Figure 4).15 Most poorly differentiated and undifferentiated thyroid carcinomas are 
thought to arise from pre-existing well-differentiated thyroid carcinomas through 
additional genetic events.  Several genes have been implicated in the pathogenesis of 
thyroid cancer which include: point mutations in BRAF, RAS, CTNNB1, and TP53; and 
gene rearrangement in BRAF, RET, NTRK1, and PPARG  (Table 3).15 BRAF(V600E) 
mutation is the most commonly encountered point mutation in PTCs and has been 
reported in varying percentages from 29 – 69%.41-49 A recent report by The Cancer 
Genome Atlas Research Network (TCGA) has further clarified the genomic landscape of 
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PTCs.41 Majority of the PTCs appear to be driven by a single mutually exclusive point 
mutation (most commonly either BRAF or RAS) or gene fusions. Additionally, PTCs can 
be subclassified into classical V600E BRAF-like PTCs and RAS-like PTCs. Thyroid 
samples were ranked by BRAF(V600E) – RAS score (BRS), with BRS being strongly 
associated with driver mutation status, thyroid differentiation score, histology and 
follicular fraction. Differential activation of molecular pathways depending on the driver 
mutations was thought to be the underlying mechanism – classical PTCs were more 
BRAF(V600E)-like on the thyroid differentiation score whereas the histological variants 
of follicular, tall cell and other variants of PTCs were more RAS-like on the thyroid 
differentiation score.  
 
Thus a test that can help differentiate between a malignant thyroid nodule from a benign 
one, predict tumor aggressiveness and facilitate cancer surveillance would be extremely 
helpful. Currently, there are two proprietary tests that are available in United States 
targeting the intermediate and indeterminate Bethesda categories through molecular 
testing of additional FNA samples– Afirma and Thyroseq v2. Afirma gene expression 
classifier developed by Veracyte Inc. (South San Francisco, CA), costs USD $4200 per 
nodule and requires samples to be sent to a central facility. This is a “rule out” test with 
preliminary studies suggesting a high negative predictive value of 94 – 95%, but low 
positive predictive value of 15 – 37% in the indeterminate category.50,51 However, more 
recent follow up studies suggest that the test is less accurate than originally reported.51-59 
Ongoing surveillance with US and US-FNAB is still recommended if the test is negative. 
Thyroseq v2 offered by CBLPATH and developed by the University of Pittsburg Medical 
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Center Division of Molecular and Genomic Pathology costs USD $2250 and requires 
samples to be sent to a central facility. Nikiforov published a recent series of 143 patients 
with FNAB diagnosis of follicular neoplasm (FN)/suspicious for follicular neoplasm 
(SFN).60 Thyroseq v2 has been termed as “rule in” test with a high negative predictive 
value of 96% and a positive predictive value of 83%. Both of these tests are currently not 
available in Canada, require shipping the samples to a central facility and cannot be used 
for thyroid cancer surveillance. Typically, additional FNA samples are needed to carry 
out these tests, which can cause additional patient pain and anxiety. 
 
We propose an alternative test to assess the presence of thyroid cancer using circulating 
tumor DNA (ctDNA) in plasma samples. Plasma samples provide several advantages 
over the traditional FNAB or Affirma – there would be significantly less discomfort to 
the patient with a routine blood draw rather than ultrasound guided FNAB, plasma 
samples are easy to handle and most tertiary care hospitals already have a polymerase 
chain reaction (PCR) machines available. 
 
1.5 Circulating Tumor DNA (ctDNA) 
 
Cell-free nucleic acids (cfDNA) in human blood were first described in 1948 by Mandel 
and Metais.61 There was very little enthusiasm in cfDNA until in 1994 it was discovered 
that mutated RAS gene fragments in blood were from cancer cells.62  With recent 
advances in molecular technology there has been great interest in cfNA in detection and 
surveillance of cancer (Figure 5 and Figure 6). 
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cfNA is comprised of DNA, RNA and microRNAs in the plasma or serum and can be 
used as “liquid biopsy”, circumventing the need for tissue biopsy and facilitating 
surveillance of cancer. ctDNA can be released by apoptotic and necrotic cancer cells, 
actively secreted by tumor cells or after tumor cells are processed by macrophages 
(Figure 7).63-65 Although the half-life of the ctDNA is variable and estimated to be 
between 15 minutes to several hours66,67, there is constant release of tumor ctDNA. Diehl 
et al. estimated that for a tumor that weighs 100g (approximately 3 x 1010 tumor cells), up 
to 3.3% of tumor DNA enters plasma each day.68 
 
Analysis of ctDNA has several advantages. These include characterization of molecular 
profiles when tissue is not available, reflects tumor heterogeneity, allows monitoring of 
response to therapy, detect residual disease following therapy, assesses tumor evolution 
with therapy and finally allows analysis of pharmacodynamics of the chemotherapy drugs 
(Table 4). Thus genetic alterations in ctDNA are better poised as biomarkers than 
conventional proteins such as CEA or CA19-9, which are expressed both in tumor and 
normal cells.  
 
In other cancers, ctDNA levels have been shown to be higher in patients with cancer66,69 
and decrease after surgery70. However they can also be elevated in non-cancer patients 
with some overlap in the ranges.66,71 Importantly, there can be considerable variation 
amongst different tumor types.69 This underscores the importance of studying ctDNA in 
each specific cancer. 
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ctDNA, which includes coding and noncoding genomic DNA, does allow for monitoring 
of tumor specific changes and allows detection of genetic and epigenetic changes within 
the patient.  Microsatellite instability, loss of heterozygosity, mutations, polymorphisms, 
methylation and integrity can be assessed in ctDNA samples. These have been 
extensively studied in various tumor types including bladder, breast, cervical, colorectal, 
hepatocellular carcinoma, lung, non-hodgkin’s lymphoma, melanoma, ovarian, pancreatic 
and prostate cancers.reviewed in 72  
 
ctDNA has been used for prognostication purposes. KRAS hotspot mutations and 
CDKN2A hypermethylation in patients with colorectal cancer was investigated by 
Lecomte et al. The 2-year survival rate was 100% in patients who did not KRAS 
mutations or CDKN2A gene promoter hypermethylation.73 In addition patients who had 
residual detectable ctDNA after surgery relapsed within 1 year.68 
 
Tumor heterogeneity is a recognized pitfall of tumor tissue sampling, with detection of 
ctDNA providing an avenue to potentially mitigate this. Kuo et al. showed that ctDNA 
provides a better representation of the overall cancer than focal primary site tumor 
biopsies.74 
 
ctDNA can be used as a predictive biomarker to monitor response to therapy as well as 
for prognostication. Tie et al. found that in metastatic colorectal cancer, ctDNA was 
detectable in plasma and early changes in ctDNA during chemotherapy predicted the 
radiologic response, which was seen later in the time course.75 Bettegowda et al. in 31 
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patients with colorectal cancer found 70 somatic mutations that were not detected in 
tumor or plasma before initiation of EGFR blockade.69 They also found that colorectal 
tumor patients who had metastatic disease with low levels of ctDNA lived significantly 
longer than patients with higher levels. A similar association has been reported in breast 
cancer patients as well.76 
 
Following the amount of ctDNA and the genetic alterations of ctDNA over time can 
enable real time surveillance of cancer, early detection and guide therapeutic 
management. Additionally, ctDNA can theoretically account for genetic heterogeneity 
within the tumor.  Other important advantage is that plasma is easier to collect and 
process, and health laboratories in most hospitals have readily available technology for 
molecular processing. Role of ctDNA has not been thoroughly investigated in thyroid 
cancer.  
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1.6 Hypothesis 
 
PTC nodules harboring BRAF(V600E) ctDNA will shed BRAF(V600E) ctDNA in blood.  
Thus BRAF(V600E) ctDNA can be used to differentiate between PTC and benign 
nodules. 
 
1.7 Objectives 
 
1. Detect BRAF(V600E) ctDNA in preoperative plasma samples of patients undergoing 
thyroid surgery for nodular thyroid disease. 
2. Compare BRAF(V600E) ctDNA levels in preoperative and postoperative plasma 
samples of patients undergoing thyroid surgery for nodular thyroid disease. 
3. Determine concordance of BRAF(V600E) between preoperative plasma samples and 
the corresponding FFPE sample of index thyroid nodule. 
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2 Methods 
 
2.1 Patient Recruitment 
 
Patients referred to the Otolaryngology – Head and Neck Surgery Clinic at the London 
Health Sciences Centre for thyroid nodules from April 2014 to March 2015 were 
approached for participation in the study. 
 
2.1.1 Eligibility 
 
Inclusion criteria included patients over the age of 18 and those scheduled to undergo 
partial or total thyroidectomy for their thyroid nodules.  
 
Exclusion criteria included previous cancer that is known to be positive for 
BRAF(V600E) mutation (such as melanoma, lung cancer and colon cancer). 
 
2.1.2 Ethics Board Approval 
 
Patients were recruited as per the London Health Sciences Center (LHSC) Research 
Ethics Board Approval (see Appendix D, Appendix E, Appendix F and Appendix G). 
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2.1.3 Sources of Funding 
 
This study was supported by a grant from The Thyroid Cancer Foundation – London 
Chapter and internal funding from the Department of Otolaryngology – Head and Neck 
Surgery. 
 
2.2 Specimen Collection 
 
Patient’s blood was collected in 5 mL EDTA coated blood collection tubes by the LHSC 
lab. This was then promptly transferred to our lab and blood was processed. Blood was 
separated into plasma and red blood cells by centrifuging at 1000g for 10 minutes at 
room temperature. Plasma was then pipetted out and aliquoted in 1 ml cryovials and 
frozen at -80°C. 
 
2.3 Isolation of Circulating Nucleic Acids 
 
Previously processed and frozen 1 ml aliquots of plasma samples were thawed and 
equilibrated to room temperature. QIAamp circulating nucleic acid kit (Cat no. 55114) 
was used using a vacuum manifold for isolation of circulating nucleic acids. 100 ul of 
Proteinase K was pipetted in a 50 ml centrifuge tube. 1 ml of plasma was added into the 
tube. 0.8 ml of Buffer ACL (containing 1 ug carrier RNA) was added and the mixture 
was vortexed and incubated at 60°C for 30 min. 1.8 ml of Buffer ACB was added to the 
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lysate and vortexed. The lysate-Buffer ACB mixture was incubated on ice for 5 mins. 
The mixture was then applied into the QIAamp Mini Column placed in the vacuum 
manifold. Once the mixture was completely through the column, 600 ul of Buffer ACW1 
was then applied. Once Buffer ACW1 was completely through the column, 750 ul of 
Buffer ACW2 was then applied. Once Buffer ACW2 was completely through the 
column, 750 ul of ethanol was then applied. The column was then removed from the 
vacuum manifold and placed in a collection tube and centrifuged at 14,000 rpm for 3 
min. The column was placed in a new collection tube and incubated at 56°C for 10 min to 
dry the membrane. The column was then placed in new elution tube and 100 ul of Buffer 
AVE was applied to the center of the membrane and incubated at room temperature for 3 
mins. Thereafter, the column was centrifuged for 1 min at 21,000g to elute the nucleic 
acids. Concentration of the nucleic acids was measured using a NanoDrop 
spectrophotometer. 
 
2.4 Isolation Of Nucleic Acids From Formalin Fixed Paraffin 
Embedded (FFPE) Samples 
 
Index thyroid nodules were identified on the paraffin embedded post-surgical specimens. 
Cores were obtained and nucleic acids were extracted using the QIAamp DNA FFPE 
tissue kit (Cat no. 56404). 1 ml xylene was added to the core FFPE specimens and the 
microcentrifuge tube was vortexed and then centrifuges at 14,000 rpm for 2 min. The 
supernatant was carefully removed and 1 ml of ethanol was added to the pellet. The 
mixture was vortexed and then centrifuged at 21,000g for 2 min. The tube was then 
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incubated at 37°C until the residual ethanol had evaporated. The pellet was then 
resuspended in 180 ul Buffer ATL followed by addition of 20 ul of proteinase K and 
mixed by vortexing. The samples were then incubated at 56°C for at least 1 hr (or until 
the sample had been completely lysed). Thereafter the samples were incubated at 90°C 
for 1 hr. The samples were then briefly centrifuged and 200 ul of Buffer AL was added 
followed by addition of 200 ul of ethanol. After brief centrifugation, the entire lysate was 
transferred to a QIAamp MinElute column and centrifuged at 7,000g for 1 min. The 
column was placed in a clean collection tube and centrifuged at 21,000g for 3 min. The 
column was placed in a clean microcentrifuge tube and 100 ul of Buffer ATE was applied 
for elution and it was incubated for 5 min. The column was then centrifuged at 21,000g 
for 1 min. Concentration of the nucleic acid was measured using a NanoDrop 
spectrophotometer. 
 
2.5 Quantitative Polymerase Chain Reaction (qPCR) for 
BRAF(V600E) 
 
The Qiagen QuantiTect Multiplex PCR Kit (Cat No. 204543) was used for qPCR. 
Briefly, a 20 ul reaction with 2X QuantiTect Multiplex PCR Master Mix, 4 uM (0.04 ul 
of 100 uM) forward primer, 4 uM (0.04 ul of 100 uM) reverse primer, 4 uM (0.04 ul of 
100 uM) probe were used. RNAse-free water was used to bring the final volume of each 
reaction to 20 ul. 0.2 ul of DNA template was used in each 20 ul reaction. See Table 5 for 
reaction setup. Each reaction included primer-probe sets specific for wildtype sequence 
of the BRAF gene (this sequence was in an exon that is not known to harbor any 
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mutations) and the BRAF(V600E) mutation (Figure 8 and Table 6). Table 7 outlines the 
cycling conditions.  
The presence of wild type BRAF was used as an internal control for the qPCR reaction. 
Dilutions of 1:1, 1:10, 1:100, 1:250 of the BHT-101 cell line were used for standard 
curve generation. ASH-3 cell line was used as negative control. Baseline was determined 
based on the negative control. Cycle threshold (Ct) was determined where the 
amplification plot crosses the baseline. Each sample was done in duplicates – 
amplification plots of duplicates were averaged and a single curve was generated to 
determine the Ct (Figure 9). Each sample was repeated at least twice. Ct for each sample 
was then used to determine the amount of BRAF and BRAF(V600E) mutation using the 
standard curve (Figure 10). The relative amount of BRAF(V600E) was calculated by the 
following formula: BRAF(V600E ) / BRAF WT % = [V600E] / [WT] x 100. Selected 
samples which were positive and negative for BRAF(V600E) mutation were sent for 
Sanger sequencing to confirm the qPCR findings.   
 
2.6 Statistical Analysis 
 
Statistical Analysis was done using SPSS. Student’s t-test was done to compare pre-
operative and post-operative BRAF(V600E) ctDNA. Fischer’s exact test was used to 
determine the association between detectable BRAF(V600E) ctDNA in preoperative 
plasma samples and pathologic characteristics. 
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3 Results 
 
3.1 Patient Characteristics 
 
A total of 61 patients were recruited.  55 (90.2%) patients were being considered for 
surgery and six (9.8%) patients were being considered for iodine radiation therapy for 
locoregional recurrence and were being considered for iodine radiation therapy. 21 
(34.4%) were males and 40 (65.6%) were females. Of those 55 patients who underwent 
surgery, final pathology of the thyroid nodules showed 13 (21.3%) were benign, 26 
(42.6%) were classical PTC, 13 (21.3%) were non-classical PTC, 3 (4.9%) were FTC. 
See Table 8 for baseline patient characteristics and final pathology of the index nodule. 
 
Of those 55 patients with preoperative samples and being considered for surgery, 
postoperative samples were obtained from 37 patients (67.3%). 12 (32.4%) were males 
and 26 (67.6%) were females. Final pathology of the corresponding index thyroid nodule 
showed 9 (21.6%) were nodular hyperplasia, 18 (48.6%) were classical PTC, 8 (21.6%) 
were non-classical PTC, 3 (8.1%) were FTC. See Table 9 for paired preoperative and 
postoperative patient characteristics and final pathology of the index nodule. 
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3.2 BRAF(V600E) detection in preoperative samples in 
patients with thyroid nodules 
 
A total of 9/61 (14.8%) patients had detectable BRAF(V600E) in the preoperative plasma 
samples (Figure 11). In patients with final diagnosis of nodular hyperplasia, 0/13 (0%) 
patients had detectable BRAF(V600E) ctDNA in the preoperative plasma samples. In 
patients with final diagnosis of classical PTC, 8/26 (30.8%) patients (patients 1, 6, 39, 40, 
41, 42, 57, 63) had detectable BRAF(V600E) ctDNA in the preoperative plasma samples. 
In patients who had underwent previous thyroidectomy and had a metastatic locoregional 
recurrence of classical PTC, 0/2 (0%) patients had detectable BRAF(V600E) ctDNA in 
the preoperative plasma samples. In patients who had underwent previous thyroidectomy 
and had a metastatic locoregional recurrence of non-classical PTC, 1/4 (25%) patients 
(patient 26) had detectable BRAF(V600E) ctDNA in the preoperative plasma samples.  
 
3.3 Ability of BRAF(V600E) ctDNA to detect classical 
papillary thyroid cancer 
 
Using the pathologic diagnosis of the index thyroid nodule as the standard, presence of 
BRAF(V600E) ctDNA in preoperative plasma samples was used to differentiate between 
classical PTCs and benign thyroid nodules (Table 10). All the patients with detectable 
BRAF(V600E) ctDNA had classical PTCs and none of the benign thyroid nodules had 
detectable BRAF(V600E) ctDNA. This was statistically significant (p < 0.05). 
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3.4 BRAF(V600E) detection before and after surgery in 
patients with thyroid nodules 
 
37 patients were followed post-operatively with an additional blood draw at one month 
follow up. 6/37 (16.2%) patients had detectable BRAF(V600E) ctDNA in preoperative 
plasma samples and all of them decreased postoperatively (p-value < 0.05), with five 
patients having non-detectable BRAF(V600E) postoperatively (Figure 12).  
 
The results were further analyzed based on the final histology of the index thyroid 
nodule. None of the patients 0/8 (0%) with a final diagnosis of nodular hyperplasia had 
detectable BRAF(V600E) ctDNA (Figure 13). 6/18 (33.3%) patients with a final 
diagnosis of classical PTC had detectable BRAF(V600E) ctDNA and they all decreased 
post-operatively (Figure 14) (p-value < 0.05). None of the patients with final diagnosis of 
non-classical PTC - 0/8 (0%) (Figure 15) and FTC - 0/3 (0%) (Figure 16) had detectable 
BRAF(V600E) ctDNA. 
 
3.5 Correlation of BRAF(V600E) ctDNA with classical PTC 
thyroid cancer staging 
 
5/6 (83.3%) patients with detectable preoperative BRAF(V600E) ctDNA and final 
diagnosis of classical PTC had higher T-stage (T3) compared to 1/6 (16.7%) patient had a 
lower T-stage disease. This was not statistically significant (p-value > 0.05) (Table 11). 
No association was noted with detectable levels of BRAF(V600E) ctDNA and nodal 
metastases and extra-thyroidal extension (ETE) (p > 0.05). 
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3.6 Detection of BRAF(V600E) in FFPE samples and 
concordance with the presence of BRAF(V600E) ctDNA in 
preoperative plasma samples 
 
To assess the concordance between preoperative BRAF(V600E) ctDNA and 
BRAF(V600E) mutational status of the index thyroid nodule, FFPE samples were 
obtained and mutational status for BRAF(V600E) was determined (see Table 12). In 
patients with final diagnosis of nodular hyperplasia: 8/8 (100%) did not have 
BRAF(V600E) mutation in both FFPE and preoperative ctDNA samples. In patients with 
final diagnosis of classical PTC: 4/18 (22.2%) patients had detectable BRAF(V600E) 
mutation in both FFPE and preoperative plasma ctDNA samples (see Figure 17), 3/18 
(16.7%) did not have BRAF(V600E) mutation in both FFPE and preoperative ctDNA 
samples, 9/18 (50%) patients had BRAF(V600E) mutation in FFPE sample but not in the 
preoperative plasma sample, and 2/18 (11.1%) patient had BRAF(V600E) mutation in  
preoperative ctDNA plasma sample but not in the FFPE sample.  
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4 Discussion 
 
The results of this study indicate that ctDNA may have a role in diagnosing thyroid 
cancer and its surveillance. US-FNAB is highly accurate in ruling out thyroid cancer in 
low risk biopsies and ruling in cancer high risk categories (suspicious and positive for 
malignancy). The specificity decreases in the indeterminate/intermediate group (Table 2). 
Tests assessing the molecular profile of the thyroid nodules are available. However, 
financial considerations as well as the necessity to send samples to a central repository is 
a major barrier for these tests.50,60 Additionally patients continue to require follow up US-
FNAB on regular intervals. Moreover these tests would not be helpful in tumor 
surveillance.  
 
BRAF(V600E) was chosen for this pilot study as it is the most common genetic alteration 
noted in PTCs and PTCs is the most common type of well-differentiated thyroid cancer.41 
There have been varying reports of detection of BRAF(V600E) ctDNA in plasma of 
patients with thyroid cancer ( Table 14 lists relevant studies). Bettegowda et al. attempted 
to detect ctDNA in a multitude of tumor types, however only 4 patients in their study 
(1%) had thyroid cancer.69 Moreover the mutations detected were all in different genes or 
codons. Pupilli et al. studied 19 patients with thyroid cancer with pre-operative and post-
operative blood testing.  They found that 12/17 (71%) of patients had non-detectable 
BRAF(V600E) ctDNA post-operatively and the other 5 patients had detectable levels 
post-operatively but they were significantly lower compared to the pre-operative levels.77 
Cradic et al. reported BRAF(V600E) ctDNA in 20 (11.6%) of the 173 thyroid cancer 
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patients correlating with the presence of active disease at the time of the blood draw.78  
Chuang et al. found that 3/14 (36%) of patients with PTC had BRAF(V600E) ctDNA.79 
Kim et al. found BRAF(V600E) ctDNA in only 6.1% of the patients (3/49) with all three 
patients having lateral lymph node or lung metastasis.80 Zane et al. reported 
BRAF(V600E) ctDNA in 0% of the patients (0/181) as they were unable to analyze 
ctDNA.81  
 
We successfully detected BRAF(V600E) ctDNA in 9/61 (14.8%) patients with thyroid 
nodular disease selected for surgery. Comparing the paired plasma samples, overall 6/37 
(16.2%) had detectable BRAF(V600E) ctDNA with significant decline in all six patients 
post-operatively.  0/8 (0%) patients with nodular hyperplasia had detectable 
BRAF(V600E) preoperative plasma ctDNA, and the levels were non-detectable 
postoperatively. Based on the molecular profiling reported by the TCGA group, we 
decided to further classify the PTCs into classical and non-classical PTCs. 6/18 (33.3%) 
classical PTC patients had detectable BRAF(V600E) preoperative plasma ctDNA – with 
five patients having non-detectable BRAF(V600E) ctDNA levels post-operatively, while 
one of the patients had a significant decline but remained detectable. This patient had 
undergone total thyroidectomy, right central neck dissection and right neck dissection for 
this disease. Intra-operatively, recurrent laryngeal nerve was encased in tumor and had 
positive margins on the final pathology. Additionally, this patient had undergone SPECT 
CT after his radioactive iodine treatment which showed two focal areas of uptake within 
the thyroid bed suggesting residual disease. Thus drop in the BRAF(V600E) ctDNA 
levels postoperatively may have an important role in cancer surveillance. 
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In our study, we found that 0/8 (0%) patients with nodular hyperplasia on final pathology 
had BRAF(V600E) ctDNA. Previous reports have suggested that up to 5.4% of thyroid 
nodules determined to be benign on FNA can harbor BRAF(V600E) mutations, and when 
combined with 2 or more high risk ultrasound features 88% are malignant on final 
pathology.82 It has been speculated that these BRAF(V600E) positive “benign” thyroid 
nodules may in fact be pre-malignant and would eventually turn malignant.83 
Additionally, although pathology is the gold standard sampling error cannot be 
discounted. During tissue processing only representative samples are typically obtained 
especially in larger thyroid nodules and thus it is plausible that foci of cancer maybe 
missed resulting in under-diagnosis of cancer. Patient 42 was initially diagnosed as 
benign thyroid nodule on final pathology specimen, however after the study results 
indicated that the patient had detectable BRAF(V600E) ctDNA in preoperative plasma 
samples and subsequent decline in the levels after surgery, the pathology specimen was 
reviewed and was diagnosed with classical PTC. This was confirmed with the HMBE-1 
immunostaining as well.  
 
Although our results were not statistically significant, there was a trend with correlation 
of BRAF(V600E) ctDNA with T-stage.; no correlation with ETE or nodal metastasis was 
noted. We speculate that with increased sample size all three of these poor pathologic 
indicators (T-stage, ETE and nodal metastases) would all be associated with 
BRAF(V600E) ctDNA. BRAF(V600E) mutation in PTC has been shown to correlate with 
poorer prognosis.84 Tufano et al. included 14 studies in their meta-analysis to assess the 
24 
prognosis of PTC in the presence of BRAF(V600E).85 Risk ratios in BRAF(V600E) 
positive patients were 1.93 for PTC recurrence, 1.32 for lymph node metastasis, 1.71 for 
ETE, 0.95 for distant metastasis and 1.70 for advanced stage AJCC III/IV. It is 
conceivable that patients with BRAF(V600E) ctDNA can be treated newly developed 
BRAF(V600E) inhibitors such PLX4720, PLX4032 and sorafenib86-88.  
To assess the utility of BRAF(V600E) ctDNA in distinguishing benign versus malignant 
thyroid pathology, BRAF mutational status in the FFPE index thyroid nodule was 
assessed. 4/6 (66.7%) classical PTC patients who had detectable BRAF(V600E) ctDNA 
also had BRAF(V600E) mutation in the FFPE samples and 2/6 (33.3%) patients had FFPE 
samples with no BRAF(V600E) detectable in FFPE but present in ctDNA.. Chuang et al. 
reported 3/5 (60%) patients who had detectable BRAF(V600E) ctDNA compared to the 
corresponding FFPE tissue.79 Cradic et al. in their study reported one (11.11%) patient 
out of nine having detectable BRAF(V600E) ctDNA while the corresponding FFPE 
sample was negative for BRAF(V600E).78 Although 11 more patients had detectable 
BRAF(V600E) ctDNA their FFPE status was not known. Pupilli et al. also had 3/9 
(33.3%) patients who had detectable BRAF(V600E) ctDNA but did not have 
BRAF(V600E) mutation in the corresponding FFPE tissue.77 In contrast to our study, the 
concordance between detectable BRAF(V600E) ctDNA and FFPE BRAF(V600E) 
mutational status was statistically significant.77 In our study, 2/6 (33.3%) patients with 
detectable BRAF(V600E) in the FFPE samples but not in ctDNA. Sampling error could 
have affected the inability to detect BRAF(V600E) in the FFPE samples, resulting in poor 
correlation of circulating and primary tumor BRAF(V600E) status observed in our study. 
Thyroid cancer is often a multi-focal disease with tumor heterogeneity. It has been 
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demonstrated that BRAF(V600E) can be acquired as a secondary change during tumor 
progression or it might be limited to subclone or separate focus in a multifocal tumor.83,89 
As previously mentioned, sampling error was noted in one of our samples; patient 42 
who was initially diagnosed with benign nodular hyperplasia on pathology but after 
detectable BRAF(V600E) ctDNA and review of the pathology, a focus of HBME-1 
immunostain positive classical PTC was noted. It is also likely that the index nodule may 
be BRAF mutant but does not happen to shed significant BRAF(V600E) DNA due to 
biological factors including tumor size, invasion and nodal metastases resulting in 
negative ctDNA levels. Additionally it is important to remember that BRAF(V600E) 
ctDNA can be positive in plasma in other malignancies including melanoma, lung cancer 
and colorectal cancer.43,69 The fact that the levels declined to non-detectable levels in our 
study in that patient suggest that the source of the BRAF(V600E) ctDNA was in fact 
thyroid tissue. 
 
5 Conclusion and Future Directions 
 
In summary, our study shows that BRAF(V600E) ctDNA can differentiate between 
malignant classical PTC thyroid cancer and benign nodules. Postoperative decline in 
BRAF(V600E) ctDNA suggests its utility as a potential marker of surveillance marker in 
a subset of thyroid cancers. Further work is needed to delineate its utility to identify 
cancers with higher T-stage, ETE and nodal metastasis.  
We are continuing to recruit more patients to increase the power of the study. Next 
generation sequencing (NGS) is a newer technology with ability to detect point 
26 
mutations, copy number variations and translocations. Ion-Torrent NGS platform will be 
used to increase the sensitivity of the detection in. Current study only included 
BRAF(V600E) however a host of additional driver mutations including point mutations, 
copy number variations and translocations have been identified in thyroid cancer.41 NGS 
will provide a platform to include an expanded panel of genes thus increasing the 
coverage of mutations. 
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Appendices 
 
Appendix A: Figures 
 
Figure 1: Age-standardized incidence rates (ASIR) for thyroid cancer in males and 
females in Canada, 1986 – 2015. Data from 2011 to 2015, represented by dashed lines is 
predicted.  
 
  
 
 
Data from Canadian Cancer Society's Advisory Committee on Cancer Statistics
5
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Figure 2: Different types of thyroid cancers. Thyroid gland is made of two cell types – 
follicular cells and parafollicular cells. Majority of the thyroid cancers arise from the 
follicular cells and papillary thyroid cancer is the most common type of thyroid cancer. 
 
 
 
 
 
Modified from Caria and Vanni 13 
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Figure 3: Algorithm for the evaluation of patients with one or more thyroid nodules. 
Patients initially undergo characterization of the thyroid nodule as well as their thyroid 
function status. Patients then undergo FNA. Further management of thyroid nodule 
depends on the results of the FNA. 
 
 
 
 
Modified from American Thyroid Association Guidelines Taskforce on Thyroid, et al. 16 
39 
Figure 4: Proposed model of thyroid carcinogenesis. Three distinct pathways are 
proposed for neoplastic transformation and proliferation of thyroid follicular cells: hyper-
functioning follicular thyroid adenoma, FTC and PTC. Most poorly differentiated and 
undifferentiated thyroid carcinomas are thought to arise from pre-existing well-
differentiated thyroid carcinomas through additional genetic events.  
 
 
 
 
 
 
Modified from Kondo, et al. 15 
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Figure 5: Publications of ctDNA in Pubmed. There has been a recent explosion of 
publications investigating ctDNA. Y-axis represents number of publications. X-axis 
represents years. 
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Figure 6: Important studies investigating cfDNA.  
 
 
 
 
 
 
 
Modified from Schwarzenbach, et al. 72  
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Figure 7: Sources of cell free nucleic acids include necrosis, apoptosis and secretion by 
tumor and macrophages. These can then be detected in blood.  
 
 
 
 
Modified from Schwarzenbach, et al. 72  
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Figure 8: qPCR primers were designed for non-mutated conserved BRAF region and 
BRAF(V600E) mutation. The non-mutated conserved BRAF region was used as an 
internal control of the qPCR reaction.  
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Figure 9: Example of qPCR amplification plot of BRAF(V600E) with BHT-101 DNA 
standards and patient ctDNA sample. ASH-3 cell line DNA was used as negative control. 
Y-axis represents the fluorescence and X-axis represents the number of cycles. Baseline 
was determined based on the negative control. Ct was determined where the 
amplification plot crosses the baseline. Each sample was done in duplicates – 
amplification plots of duplicates were averaged and a single curve was generated to 
determine the Ct. 
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Figure 10: Example of standard curve generation from the Ct value obtained from BHT-
101 standards. 1:1, 1:10, 1:100 and 1:250 dilution of BHT-101 was used as standard for 
both non-mutated conserved BRAF region and BRAF(V600E). Y-axis represents Ct and 
X-axis represents amount of DNA in nanograms. The relative amount of BRAF(V600E) 
was calculated by the following formula: BRAF(V600E)/ BRAF WT % = [V600E] / [WT] 
x 100. 
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Figure 11: Detection of BRAF(V600E) in preoperative samples as determined by relative 
amount of BRAF(V600E) (mean ±SE). 9/61 (14.8%) patients had detectable 
BRAF(V600E) ctDNA. Y-axis represents average preoperative BRAF(V600E) /BRAF 
wildtype percentage. X-axis represents individual patients. 
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Figure 12: BRAF(V600E) ctDNA detection as determined by relative amount of 
BRAF(V600E) in patients with paired preoperative and postoperative samples (N = 37).  
6/37 (16.2%) patients had detectable levels preoperatively and they all declined 
postoperatively. Y-axis represents average BRAF(V600E) /BRAF wildtype percentage. X-
axis represents preoperative and postoperative samples. Each datapoint and 
corresponding line represents an individual patient. 
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Note: There is overlap of samples 40 and 42 in the graphic representation. Only means have been shown 
for each sample. Patients with non-detectable ctDNA in either preoperative or postoperative samples are 
not represented in this figure.   
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Figure 13: BRAF(V600E) ctDNA detection as determined by relative amount of 
BRAF(V600E) in paired preoperative and postoperative samples of patients with final 
pathology suggestive of nodular hyperplasia (N = 8). 0/8 (0%) patients had detectable 
levels preoperatively and they all declined postoperatively. Y-axis represents average 
BRAF(V600E) /BRAF wildtype percentage. X-axis represents preoperative and 
postoperative samples. Each datapoint and corresponding line represents an individual 
patient. 
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Figure 14: BRAF(V600E) ctDNA detection as determined by relative amount of 
BRAF(V600E) in paired preoperative and postoperative samples of patients with final 
pathology suggestive of classical PTC (N = 17). 6/18 (33.3%) patients had detectable 
levels preoperatively and they all declined postoperatively. Y-axis represents average 
BRAF(V600E) /BRAF wildtype percentage. X-axis represents preoperative and 
postoperative samples. Each datapoint and corresponding line represents an individual 
patient. 
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Note: There is overlap of samples 40 and 42 in the graphic representation. Only means have been shown 
for each sample.  
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Figure 15: BRAF(V600E) ctDNA detection as determined by relative amount of 
BRAF(V600E) in paired preoperative and postoperative samples of patients with final 
pathology suggestive of non-classical PTC (N = 8). 0/8 (0%) patients had detectable 
levels preoperatively and they remained undetectable postoperatively. Y-axis represents 
average BRAF(V600E) /BRAF wildtype percentage. X-axis represents preoperative and 
postoperative samples. Each datapoint and corresponding line represents an individual 
patient. 
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Note: Only means have been shown for each sample.  
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Figure 16: BRAF(V600E) ctDNA detection as determined by relative amount of 
BRAF(V600E) in paired preoperative and postoperative samples of patients with final 
pathology suggestive of FTC (N = 3). 0/3 (0%) patients had detectable levels 
preoperatively and they remained undetectable postoperatively. Y-axis represents average 
BRAF(V600E) /BRAF wildtype percentage. X-axis represents preoperative and 
postoperative samples. Each datapoint and corresponding line represents an individual 
patient. 
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Note: Only means have been shown for each sample. 
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Figure 17: Concordance between FFPE samples and BRAF(V600E) ctDNA as 
determined by relative amount of BRAF(V600E) (mean ±SE) in paired preoperative and 
postoperative samples of patients with final pathology suggestive of classical PTC. 4/6 
(66.6%) patients had detectable BRAF(V600E) ctDNA and corresponding BRAF(V600E) 
in the FFPE samples. Y-axis represents average BRAF(V600E) /BRAF wildtype 
percentage. X-axis represents each individual patient. 
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Appendix B: Tables 
 
 
Table 1: Clinical features of different types of thyroid cancer.  
 
Tumour type Prevalence 
Sex ratio 
(female:male) 
Age 
(years) 
Lymph-node 
metastasis 
Distant 
metastasis 
Survival rate 
(5 year) 
Papillary thyroid 
carcinoma 
85–90% 2:1–4: 1 20–50 <50% 5–7% >90% 
Follicular thyroid 
carcinoma 
<10% 2:1–3: 1 40–60 <5% 20% >90% 
Poorly differentiated 
thyroid carcinoma 
rare–7% 0.4:1–2.1: 1 50–60 30–80% 30–80% 50% 
Undifferentiated 
thyroid carcinoma 
2% 1.5: 1 60–80 40% 20–50% 1–17% 
Medullary thyroid 
carcinoma 
3% 1:1–1.2: 1 30–60 50% 15% 80% 
 
 
Modified from Kondo, et al. 15  
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Table 2: FNAB results based on Bethesda Thyroid Nodule System 
 
Risk Category Bethesda 
Predicted 
Risk of 
Malignancy 
(%)a 
Malignancy 
Rate in 
Literature 
(%)b 
LHSC 
Malignancy 
Rate (%)c 
Recommendations 
 
Nondiagnostic/
Unsatisfactory 
1 – 4 16.8 13 
Repeat U/S guided 
FNAB 
Low Benign 0 – 3 3.7 3 Follow 
Indeterminate FLUS/AUS 5 – 15 15.9 13 – 50 
Repeat 
FNAB/Close 
followup 
Intermediate FN/SFN 15 – 30 26.1 20 – 40 
Close followup or 
diagnostic hemi-
thyroidectomy 
High 
Suspicious for 
malignancy 
60 – 75 75.2 
80 – 98 
Total 
thyroidectomy 
Malignant 97 – 99 98.6 
a – 32, b - data primarily from 32,90-94, c – unpublished 
LHSC – London Health Sciences Centre, FLUS – Follicular Lesion of Unknown Significance, AUS – 
Atypia of Unknown Significance, FN – Follicular Neoplasm, SFN – Suspicious for Follicular Neoplasm (or 
Hurthle Cell Neoplasm) 
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Table 3: Genetic alterations in different types of thyroid cancers. 
 
Genetic 
alteration 
Well-differentiated 
thyroid carcinoma 
Poorly 
differentiated 
thyroid carcinoma 
Undifferentiated 
thyroid carcinoma 
 PTC FTC   
RET 
rearrangement 
13–43% 0% 0–13% 0% 
BRAF mutation 29–69% 0% 0–13% 10–35% 
BRAF 
rearrangement 
1% Unknown Unknown Unknown 
NTRK1 
rearrangement 
5–13% Unknown Unknown Unknown 
RAS mutation 0–21% 40–53% 18–27% 20–60% 
PPARG 
rearrangement 
0% 25–63% 0% 0% 
CTNNB1 
mutation 
0% 0% 0–25% 66% 
TP53 mutation 0–5% 0–9% 17–38% 67–88% 
 
Modified from Kondo, et al. 15 
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Table 4: Clinical applications of ctDNA. ctDNA can be used for diagnosis of disease, 
predict response to treatment and prognostication by identifying early recurrence and 
determining tumor burden. 
 
 Application 
Diagnostic 
Early detection 
Monitoring of minimal residual disease 
Predictive 
Assessment of molecular heterogeneity of overall disease 
Monitoring of tumor dynamics 
Identification of genetic determinants for targeted therapy 
Evaluation of early treatment response 
Assessment of evolution of resistance in real time 
Prognostic 
Identification of high risk of recurrence 
Correlation with changes in tumor burden 
 
Modified from Heitzer, et al. 95 
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Table 5: qPCR reaction setup  
 
Component Volume Final Concentration 
2x QuantiTect Multiplex PCR 
Master Mix  
10 ul 1 x 
20x primer-probe mix 1 0.04 ul 
0.4 uM forward primer 
0.4 uM reverse primer 
0.4 uM probe 
20x primer-probe mix 2 0.04 ul 
0.4 uM forward primer 
0.4 uM reverse primer 
0.4 uM probe 
RNase-free water 9.56 ul  
Template DNA 0.2 ul  
Total reaction volume 20 ul  
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Table 6: qPCR Primer and Probe Sequences 
 
Gene Primer/Probe Sequences 
BRAF non-mutated 
exon 
Forward 5’-TAGGTGATTTTGGTCTAGCTACCGA 
Reverse 5’-GGATCCAGACAACTGTTCAAACTG 
Probe 5’-[JOE]GAATCTCGATGGAGTGGGTC 
BRAF(V600E) 
Forward 5’-GATGCACTCCAACAAAGAGAACAA 
Reverse 5’-GGTATCCATTGATGCAGAGCTAGA 
Probe 5’-[ROX]TCTCTGGGGAACGGAACTGA 
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Table 7: qPCR Cycling Conditions 
 
Step Time Temperature (°C) 
PCR initial activation step 15 min 95 
Denaturation 1 min 94 
Annealing/extension 1 min 30 sec 62 
Number of cycles 40x  
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Table 8: Baseline patient characteristics and final pathology of the index nodule. 
 
 
Preoperative Samples = 61 
 Males 21 (34.4%) 
 Females 40 (65.6%) 
 
 
 
Pathology 
Benign 13 (21.3%) 
PTC, classical 26 (42.6%) 
PTC, non-classical 13 (21.3%) 
FTC 3 (4.9%) 
Metastatic PTC, classical 2 (3.3%) 
Metastatic PTC, non-classical 4 (6.6%) 
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Table 9: Paired preoperative and postoperative patient characteristics and final pathology 
of the index nodule. 
 
Paired Samples = 37 
 Males 12 (32.4%) 
 Females 25 (67.6%) 
 
 
Pathology 
Benign 8 (21.6%) 
PTC, classical 18 (48.6%) 
PTC, non-classical 8 (21.6%) 
FTC 3 (8.1%) 
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Table 10: Detection of BRAF(V600E) in benign and classical PTC in preoperative 
plasma ctDNA samples. 
 
 
 Benign Classical PTC p-valuea 
BRAF(V600E) 
ctDNA positive 
0 8 
 
p < 0.05 
BRAF(V600E) 
ctDNA 
negative 
13 18 
a - Fischer’s exact test was used to assess for statistical significance. 
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Table 11: Correlation of BRAF(V600E) ctDNA and pathologic T-stage, N-stage and ETE 
in patients with classical PTC patients. 
 
  ctDNA positive ctDNA negative p-valuea 
T-stageb 
Low T-stage 1 7 
p > 0.05 
High T-stage 5 5 
N-stage 
0 1 6 
p > 0.05 1a 3 2 
1b 2 4 
ETE 
Absent 2 7 
p > 0.05 
Present 4 5 
a - Fischer’s exact test was used to assess for statistical significance. 
b – Low T-stage was defined to be T1 and T2. High T-stage was defined to be T3 and T4.  
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Table 12: Concordance between the mutational status of BRAF(V600E) in the FFPE 
index thyroid nodule and preoperative BRAF(V600E) ctDNA based on histology. 
 
 
  FFPE positive FFPE negative 
    
Nodular 
Hyperplasia 
ctDNA positive 0 0 
ctDNA negative 0 8 
    
PTC, classical 
ctDNA positive 4 2 
ctDNA negative 9 3 
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Table 13: Concordance between the mutational status of BRAF(V600E) in the FFPE 
index thyroid nodule and ctDNA. Numbers in each cell represent the total of benign and 
classical PTC samples. 
 
FFPE positive FFPE negative 
ctDNA positive 4 2 
ctDNA negative 9 11 
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Table 14: Comparison of findings in various studies published on ctDNA in thyroid 
cancer. 
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Appendix C: TNM Classification System for 
Differentiated Thyroid Carcinoma 
 
 Definition 
T1 Tumor diameter 2 cm or smaller 
T2 Primary tumor diameter >2 to 4cm 
T3 
Primary tumor diameter >4 cm limited to the thyroid or 
with minimal extrathyroidal extension 
T4a 
Tumor of any size extending beyond the thyroid capsule 
to invade subcutaneous soft tissues, larynx, trachea, 
esophagus, or recurrent laryngeal nerve 
Tb 
Tumor invades prevertebral fascia or encases carotid 
artery or mediastinal vessels 
Tx 
Primary tumor size unknown, but without extrathyroidal 
invasion 
N0 No metastatic nodes 
N1a 
Metastases to level VI (pretracheal, paratracheal, and 
prelaryngeal=Delphian lymph nodes) 
N1b 
Metastasis to unilateral, bilateral, contralateral cervical 
or superior mediastinal nodes 
Nx Nodes not assessed at surgery 
M0 No distant metastases 
M1 Distant metastases 
Mx Distant metastases not assessed 
Stages  
 Patient age < 45 years 
Patient age 45 years or 
older 
Stage 1 Any T, any N, M0 T1, N0, M0 
Stage II Any T, any N, M1 T2, N0, M0 
Stage III  T3, N0, M0 
  T1, N1a, M0 
  T2, N1a, M0 
  T3, N1a, M0 
Stage IVa  T4a, N0, M0 
  T4a, N1a, M0 
  T1, N1b, M0 
  T2, N1b, M0 
  T3, N1b, N0 
  T4a, N1b, M0 
Stage IVb  T4b, Any N, M0 
Stage IVc  Any T, Any N, M1 
Modified from Edge and American Joint Committee on Cancer. 96 
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Appendix D: Research Ethics Board Application 
 
General Info 
FileNo:  103985  
Title:  Detection of Circulating Tumor DNA in Thyroid Cancer  
Start Date:  10/02/2014  
End Date:  31/08/2018  
Keywords:  thyroid cancer,biomarkers,circulating tumor DNA,screening test  
Project Members 
Principal Investigator 
Prefix:  Dr.  
Last Name:  Nichols  
First Name:  Anthony  
Affiliation:  Schulich School of Medicine and Dentistry\Otolaryngology  
Rank:  Assistant Professor  
Gender:  Male  
Email:    
Phone1:    
Phone2:   
Fax:   
Mailing Address:    
Institution:   
Country:   
Comments:   
 
Others 
Rank 
Last 
Name 
First 
Name 
Affiliation 
Role In 
Project 
  Rachinsky Irina 
Schulich School of Medicine and 
Dentistry\Imaging 
Co-Investigator 
Lecturer Macneil Danielle 
Schulich School of Medicine and 
Dentistry\Otolaryngology 
Co-Investigator 
  Van Uum Stan 
Schulich School of Medicine and 
Dentistry\Medicine-Dept of 
Co-Investigator 
  Fung Kevin 
Schulich School of Medicine and 
Dentistry\Oncology 
Co-Investigator 
  Barrett John   Co-Investigator 
Adjunct 
Professor 
Theurer Julie 
Health Sciences\Communication 
Sciences & Disorders 
Co-Investigator 
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Associate 
Professor 
Yoo John 
Schulich School of Medicine and 
Dentistry\Otolaryngology 
Co-Investigator 
Associate 
Professor 
Kwan Keith 
Schulich School of Medicine and 
Dentistry\Pathology 
Co-Investigator 
Research 
Assistant 
Partridge Allison 
Schulich School of Medicine and 
Dentistry\Medicine-Dept of 
Research 
Support Staff 
Resident Patel Krupal 
Schulich School of Medicine and 
Dentistry\Otolaryngology 
Student 
Common Questions 
1. Registration Information 
# Question Answer 
1.1  
Do you confirm that you have read the 
above information and that based on 
that information you are completing the 
correct form? 
Yes 
1.2  
Has this study been submitted to any 
other REB? If yes, please include the 
approval letter (or relevant 
correspondence). 
No 
1.3  
If YES is selected in question 1.2 
above, please indicate where this 
project has been submitted and when. 
  
1.4  
Indicate the funding source for this 
study or if there is no funding simply 
indicate "None". 
Self-funded 
1.5  
If you have indicated a funding source 
in question 1.4 above, please specify 
the name of the funding source selected 
as well as the title of the grant and if 
applicable the ROLA number. 
Translational Head and Neck Cancer 
Research Fund (philanthropic funds) 
1.6  
Is this a sequel to previously approved 
research?  
No 
1.7  
If YES is selected in question 1.6 
above, what is the REB number and 
what are the differences? 
  
1.8  Is this a student project? Yes - Resident/Fellow 
1.9  Is this a multi-site study? No 
1.10  
If YES has been selected in question 
1.9 above, name the lead site and 
project leader for the study. If the study 
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is administered by a Coordinating or 
Contract Research Organization (CRO) 
provide the name and contact 
information. 
1.11  
Please list the names of ALL Local 
(Western affiliated) team members who 
are working on this project. Please 
ALSO list their ROLE in the project, 
i.e. what exactly is it that the team 
member will do in this study? Please 
see the “i” for this question for 
instructions on how to link their Romeo 
accounts to this form so they have 
access to it. 
Head and Neck Surgeons (involved in 
patient recruitment, consent, coordinating 
blood draws) -John Yoo, Kevin Fung, 
Anthony Nichols, Danielle MacNeil, 
Krupal Patel Pathologists (responsible for 
reviewing the thyroid pathology and 
obtaining punch biopsies from focuses of 
tumor) -Bret Wehrli and Keith Kwan Post-
Doctoral Fellow (responsible for study 
coordination, data interpretation). -Julie 
Theurer Scientists (responsible for study 
design, mutational detection, data analysis, 
manuscript preparation) -John Barrett, 
Anthony Nichols, Krupal Patel 
1.12  
Are the investigator(s) based at any of 
the sites below or will the study utilize 
any patient data, staff resources or 
facilities within any of these sites? 
(Please indicate all applicable sites and 
read the associated notes found in the 
blue information icon above) 
LHSC - Victoria Hospital 
1.13  
If this form was started by a team 
member, has the role of Principal 
Investigator been changed to the 
Faculty member who will hold this role 
for the study? This is required for 
review of your submission, and any 
forms submitted without this change 
being made will be returned without 
being reviewed. (The blue information 
“i” has the instructions on how to 
change the role of PI.) 
Not Applicable – Principal Investigator is 
the one who started the submission form 
1.14  
Please provide a lay summary of the 
study (typically fewer than 5 lines). 
Thyroid nodules are very common, and the 
majority are benign. Nodules are typically 
evaluated with a needle biopsy, however a 
large proportion of the needle biopsies are 
non-diagnostic and surgery is offered. 
Needle biopsies can also be very 
uncomfortable for patients. A non-invasive 
blood test that can differentiate between 
benign and malignant thyroid nodules 
would be of tremendous value to better 
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guide the care of these patients. DNA that is 
shed by the tumor into the blood stream can 
be detected and serve as a screening test. 
2. Methodology 
# Question Answer 
2.1  
Outline the study rationale including 
relevant background information and 
justification. Cite references where 
appropriate. 
Thyroid nodules are extremely common, 
and can be indentified in over 50% of the 
population on ultrasounds. The first line of 
investigation for these nodules is a fine 
needle aspiration (FNA) biopsy, however a 
significant fraction of FNA results are 
indeterminate. These patients typically 
undergo a hemithyroidectomy, however 
only 15% of indeterminate biopsies prove 
to be cancer. In addition, needle biopsies 
can be very uncomfortable for patients, 
particularly if multiple passes are needed. 
Ideally a accurate non-invasive blood test 
that can distinguish between benign and 
malignant nodules would be of great utility. 
Such a test would both avoid unnecessary 
surgery in patients with benign disease and 
guide surgeons towards total thyroidectomy 
in patients with malignancy. Another 
challenge in thyroid disease is the follow up 
of thyroid cancer. Thyroglobulin is secreted 
specifically from thyroid tissue. After 
thyroidectomy, rising thryoglobulin levels 
are useful to detect recurrence in the 
majority of cases. However, small 
remenants of thyroid tissue are let in situ 
after thyroidectomy that result in an 
elevated thyroglobulin level despite the 
absence of residual cancer. More 
troublesome is a small cohort of thyroid 
cancer patients that become thyroglobulin 
negative despite demonstrable recurrent 
disease. Improved diagnostics would be 
helpful to monitor this cohort. It has been 
well established that cancers shed DNA that 
can be detected in the bloodstream. 
Mutations in oncogenes and tumor 
suppressors that are found in cancers should 
not be found in the body of healthy patients. 
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Studies in other cancers have shown that the 
detection of circulating tumor DNA 
(ctDNA) in cancer patients can serve as a 
ultra-sensitive test of disease status. Unlike 
the majority of malignacies, the majority of 
well differentiated thyroid cancers (~80%) 
have either a specific fusion (RET/PTC or 
PAX8/PPARgamma) or hotspot mutations 
in well described oncogenes (RAS, 
PIK3CA, BRAF). Thus a rather small panel 
of mutations can be tested for in plasma 
samples as a screening and surveillance test 
for a large fraction of thyroid cancers. 
Although well described in other cancers, 
ctDNA has largely not been investigated in 
thyroid disease with the exception of a pilot 
study that evaluated only BRAF mutations 
(PUBMED ID: 19850689). 
2.2  
Please provide a clear statement of the 
purpose and objectives of this project 
(one page maximum). 
1) To determine the ability to detect BRAF, 
PIK3CA, RAS mutations and RET/PTC 
and PAX9/PPARgamma fusions in the 
plasma of patients with thyroid nodules 
using a real time PCR assay. 2) To 
determine the reliability of ctDNA detection 
with malignancy on final pathology. 
2.3  
Describe the study design/methodology 
and attach all supporting documents in 
the attachments tab. 
Patients undergoing thyroid surgery with 
benign, indeterminate and malignant needle 
biopsies will be identified for study. Ten 
mL of blood will be drawn at the time of 
routine bloodwork preoperatively and at 
one month, three month, six month and one 
year follow-up with the surgeon after 
surgery. An additional 10 ml of blood 
sample will be collected immediately after 
surgery once the specimen has been 
removed. The blood will be centrifuged and 
the plasma removed. DNA will be extracted 
from the plasma and tested for mutations in 
the previously mentioned mutations and 
fusions by real-time polymerase reaction 
(PCR). The cycle threshold difference 
between the wild type and mutation specific 
primers will be used to determine positivity. 
Positive PCR assays pre and post-
operatively will be compared to the results 
of surgery. A subset of the thyroidectomy 
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samples (100) will be screened by a 
pathologist. Area of tumor will be identified 
and multiple 1mm cores (up to 5) will be 
taken from the center of the tumor and 
DNA will be extracted. The above 
mentioned mutations and fusions will be 
tested for by real-time PCR. 
2.4  
Indicate the inclusion criteria for 
participant recruitment. 
1) Age 18 or older 2) Scheduled to undergo 
partial or total thyroidectomy for nodules 
2.5  
Considering your inclusion criteria 
listed above, what is the basis to 
exclude a potential participant? 
1) Previous cancer that is known to be 
positive for one of the tested mutations (i.e. 
melanoma which may contain BRAF 
mutations). 
2.6  
If using patients, describe the usual 
standard of care at the study site(s) for 
this population (including diagnostic 
testing, frequency of follow up visits). 
All thyroidectomy patients undergo pre and 
post-operative testing to assess thyroid 
function (TSH, T3, T4), parathyroid levels 
(PTH), and calcium levels. At the very least 
this occurs at initial consultation and at the 
follow up at ~3-4 weeks to discuss the 
pathology. Thus the patient will be 
undergoing a blood draw at these 
appointments. The sample (10mL) for 
mutational testing would be draw at the 
same time using blood tubes provided by 
the principal investigator, thus no additional 
blood draws or hospital resources are 
required for this study. 
2.7  
Describe the study procedures and any 
study specific testing that will be done, 
outside of standard care. 
Blood and tumor mutational analysis by 
real-time PCR will be tested. As this is not 
done in a certified lab setting and the 
significance of the findings are not yet 
known, results will not be reported to the 
patient. 
2.8  
How many participants over the age of 
18 from London will be enrolled in 
your study? This includes hospital and 
university sites within London. 
Up to 400. 
2.9  
How many participants under the age 
of 18 from London will be enrolled in 
your study? This includes hospital and 
university sites within London. 
0 
2.10  
How many participants over the age of 
18 will be included at all study 
locations? (London + Other locations = 
Total) 
Up to 400. 
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2.11  
How many participants under the age 
of 18 will be included at all study 
locations? (London + Other locations = 
Total) 
0 
2.12  
Describe the method(s) of data 
analysis. 
Mutational and fusion protein analysis will 
be carried out by real-time PCR testing. Pre 
and post-operative mutational levels will be 
compared as will the presence of mutations 
in patients with benign and malignant 
thyroid nodules. 
2.13  
How will the results of this study be 
made public? 
Peer reviewed publication 
2.14  
If report to participants or other is 
selected above, please explain. 
  
2.15  
Briefly provide any plans for provision 
of feedback of results to the 
participants. 
No feedback will be provided as the 
significance of the mutation analysis is not 
yet determined and the testing is not carried 
out in a certified lab. 
2.16  
Does this study include any use of 
deliberate deception or withholding of 
key information that may influence a 
participant's performance or response? 
No 
2.17  
If YES in question 2.16 above, describe 
this process and justification including 
how the participants will be debriefed 
at some point. Please include the 
debriefing script. 
  
3. Risks and Benefits 
# Question Answer 
3.1  
List any potential anticipated benefit to 
the participants. 
None other than potentially improving the 
care of future patients with thyroid disease. 
3.2  List the potential benefits to society. 
Blood mutational testing may offer a non-
invasive way to assess the risk of 
malignancy in thyroid nodules. This may 
help to avoid unnecessary surgery in 
patients with benign nodules and identify 
patients that would benefit from total 
thyroidectomy versus two step 
thyroidectomy. This study may also lead to 
a more accurate way to follow patients with 
thyroid cancer. 
3.3  
List any potential risks to study 
participants. 
None. 
75 
3.4  
List any potential inconveniences to 
daily activities. 
None. All the additional blood samples 
would be collected at the time of blood 
draws needed for clinical care. 
4. Recruitment and Informed Consent 
# Question Answer 
4.1  
How will potential participants be 
contacted and recruited? Select all that 
apply. A copy of all recruitment tools 
that will be used must be included with 
this submission in the attachments tab. 
Investigators will approach their own 
patients/students 
4.2  
Please explain in detail your selection 
from 4.1 and how it will be used to 
recruit participants. 
The investigators including the four 
surgeons (Yoo, Nichols, Fung, MacNeil, 
Patel (resident)) and three endocrinologists 
(Morrison, Van Uum, Paul) will be 
responsible for patient recruitment in clinic 
preoperatively. The letter of information 
and consent will be used to provide a 
description of the study to potential 
subjects. Drs. Nichols, Barrett and Mymryk 
will be responsible for the mutational 
testing. 
4.3  
Which research team members will be 
recruiting the potential participants? 
See above. 
4.4  
Does the Principal Investigator have 
any relationship to the potential 
participants? 
Yes, the principal investigator will be 
recruiting subjects, some of which will be 
his own patients. 
4.5  
Does the person recruiting the 
participants have any relationship or 
hold any authority over the potential 
participants? 
Yes 
4.6  
If you have answered "Yes" to either 
4.4 or 4.5, please explain here. 
The majority of time, the person recruiting 
participants will be the treating physician. 
As this is a low/no risk study the chance of 
harm is negligible. 
4.7  
What method of obtaining consent will 
you use for participants? A copy of all 
forms being used for obtaining consent 
must be included with this submission. 
Written Consent 
4.8  
If you are unable to obtain consent or 
assent using one of the methods listed 
above, please explain here. 
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4.9  
Indicate if you will be recruiting from 
any of the following groups specifically 
for this study. (select all that apply) 
Patients 
4.10  
Will minors or persons not able to 
consent for themselves be included in 
the study? 
No 
4.11  
If YES is selected in question 4.10 
above, describe the consent process and 
indicate who will be asked to consent 
on their behalf and discuss what 
safeguards will be employed to ensure 
the rights of the research participant are 
protected.  
  
4.12  
When the inability to provide an 
informed consent is expected to be 
temporary, describe what procedures 
will be used to regularly assess capacity 
and to obtain consent if the individual 
later becomes capable of providing 
consent. Alternatively, if diminished 
capacity is anticipated for the study 
population, describe the procedure used 
to assess capacity and obtain ongoing 
consent. 
Only patients able to consent at the time of 
preoperative consultation will be recruited. 
4.13  
List any anticipated communication 
difficulties: 
None 
4.14  
Describe the procedures to address any 
communication difficulties (if 
applicable): 
not applicable. 
4.15  
Indicate what compensation, if any, 
will be provided to subjects. For 
example, reimbursement for expenses 
incurred as a result of research, 
description of gifts for participation, 
draws and/or compensation for time. 
Include a justification for this 
compensation. 
none. 
5. Confidentiality and Data Security 
# Question Answer 
5.1  
Are you collecting personal identifiers 
for this study? 
Yes 
5.2  
Identify any personal identifiers 
collected for this study. 
Full name|Health card number|Date of birth 
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5.3  
If you checked any of the personal 
information in 5.2 above, please 
explain and justify the collection of this 
identifier. 
Patients will need to be followed to 
determine if there is a difference in pre and 
post operative mutational status and if 
serum mutational status correlates with the 
tumor. This will require creation of a 
password protected secure database located 
on a hospital network drive (S drive) behind 
the hospital firewall. 
5.4  
Where will information collected as 
part of this study be stored? (select all 
that apply) 
University or Hospital network drive 
(specify below) 
5.5  
If you have indicated any of the 
locations in question 5.4, please specify 
here. 
We will create a password protected secure 
database stored on a hospital drive behind 
the hospital firewall. 
5.6  
If identifiable participant information is 
stored on a hard drive or portable 
device, the device must be encrypted. 
Describe encryption being used. 
Not applicable. 
5.7  How will you record study data? Data Collection Form|Other 
5.8  
If you select "Other" in 5.7, please 
explain why here: 
Patient data will be immediately entered 
into the secure database on the network 
server once an individual is recruited. 
5.9  
Describe the coding system to protect 
identifiable information or explain why 
the data must remain identifiable. 
All identifying information will only be 
stored in the secure database. Collected 
samples will be labelled with participant 
number only - i.e. #1, #2, #3, #4 and so on, 
to maintain patient confidentiality/privacy. 
5.10  
How will you store and protect the 
master list, signed original letters of 
information and consent documents or 
other data with identifiers? 
Paper file (Required Protection: Locked 
cabinet in locked institutional 
office)|Electronic file (local) (Required 
Protection: Password protected computer on 
a secure network behind institutional 
firewalls - specify location) 
5.11  
If any options are selected above, 
please provide the specific details here. 
Password protected secure database stored 
on a hospital drive behind the hospital 
firewall. 
5.12  
How will you store and protect data 
without identifiers? 
Not applicable. 
5.13  
If you plan to de-identify the study 
data, please describe the method of de-
identification. 
Not applicable. 
5.14  How long will you keep the study data? 
For 5 years after the completion of the 
study. 
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5.15  
How will you destroy the study data 
after this period? (If applicable) 
Delete the database. 
5.16  
Does this study require you to send data 
outside of the institution where it is 
collected? This includes data taken off-
site for analysis. Please note that 
Western/Robarts are considered off-site 
locations for hospital/Lawson based 
studies, and vice-versa. 
No 
5.17  Where will the data be sent? Not applicable. 
5.18  
Does the data to be transferred include 
personal identifiers? If yes, a data 
transfer agreement may be necessary. 
No 
5.19  
List the personal identifiers that will be 
included with the data sent off-site. 
Not applicable. 
5.20  
If you have answered yes to 5.18 please 
indicate how the data will be 
transmitted 
  
5.21  
Please specify any additional details on 
data transmission below. 
  
5.22  
Will you link the locally collected data 
with any other data sets? 
No 
5.23  
If YES is selected in question 5.22 
above, identify the dataset 
  
5.24  
If YES is selected in question 5.22 
above, explain how the linkage will 
occur. 
  
5.25  
If YES is selected in question 5.22 
above, provide a list of data items 
contained in the dataset. 
  
5.26  
Will the data be entered into a database 
for future use? 
Yes 
5.27  
If YES is selected in question 5.25 
above, please specify where it will be 
stored, who the custodian will be, who 
will have access to the database and 
what security measures will be in place. 
The data will be stored on a password 
protected database on a hospital server (S 
Drive) behind the hospital firewall. Only 
the study investigators will have access to 
the information. 
5.28  
Please list agencies/groups/persons 
outside of your local research team who 
will have access to the identifiable data 
and indicate why access is required. 
Not applicable. 
5.29  
Western University policy requires that 
that you keep data for a minimum of 5 
years. Please indicate if you are 
Yes, data will be kept for 5 years after 
completion of the study. 
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keeping data in accordance to this 
policy, otherwise please comment on 
how your data retention will differ from 
University policy and why. If you will 
be archiving the data, please explain 
why and how here. 
6. Conflict of Interest 
# Question Answer 
6.1  
Will any investigators, members of the 
research teams, and/or their partners or 
immediate family members function as 
advisors, employees, officers, directors 
or consultants for this study? 
No 
6.2  
Will any investigators, members of the 
research team, and/or their partners or 
immediate family members have a 
direct or indirect financial interest 
(including patents or stocks) in the 
drug, device or technology employed in 
this research study? 
Yes 
6.3  
Will any investigators, members of the 
research team, and/or their partners or 
immediate family members receive any 
personal benefit (apart from fees for 
service) as a result of, or connects to 
this study? 
Yes 
6.4  
If YES is selected in any of the above, 
please describe the nature of the 
conflict of interest and how all 
conflict(s) of interest will be managed. 
The results of this study may potentially 
lead to patents and a commercial product. 
We will take the appropriate steps within 
the Western University policy if we wish to 
commercialize the findings. 
7. Industry Sponsored Protocols 
# Question Answer 
7.1  Is this an industry sponsored protocol? No 
7.2  
Billing Information - Company 
Institution: 
  
7.3  Contact Person:   
7.4  Email of Contact Person:   
7.5  Street Address:   
7.6  City:   
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7.7  Country:   
7.8  Province/State:   
7.9  Phone Number:   
7.10  Fax:   
7.11  
Contract and/or protocol reference 
number required: 
  
7.12  
Additional Sponsor Reference or 
contact information: 
  
7.13  
Do you wish to apply for a REB 
Administration Fee 
Adjustment/Waiver? 
  
7.14  
If YES to question 7.13 above, provide 
a brief written explanation indicating 
how the funding will be used, who will 
own the data or any intellectual 
property arising from the agreement 
and indicate if there are any restrictions 
imposed upon the investigator by the 
sponsor and, if so, what they are. 
  
7.15  
Do you agree to the Conditions for 
Industry Funded Research 
Investigators? 
  
7.16  
Do you agree to provide supporting 
documents? (These can be added in the 
attachments section) 
  
8. Confirmation of Responsibility 
# Question Answer 
8.1  
As the Principal Investigator I have read the Tri-Council Policy 
Statement 2 and Western University's Guidelines on Research 
Involving Human Subjects and agree to abide by the guidelines 
therein: 
http://uwo.ca/research/ethics/health_sciences/d_guidelines.html 
Yes 
8.2  
I attest that all Collaborators working on this Research Study 
(co-investigators, students, post-docs, etc.) have reviewed the 
protocol contents and are in agreement with the protocol as 
submitted; 
Yes 
8.3  
All Collaborators have read the Tri-Council Policy Statement 2 
and Western University's Guidelines on Research Involving 
Human Subjects and agree to abide by the guidelines therein; 
Yes 
8.4  
The Collaborators and I will adhere to the Protocol and 
Letter(s) of Information as approved by the REB; 
Yes 
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8.5  
Should I encounter any changes or adverse events/experiences, 
I will notify the REB in a timely manner. 
Yes 
8.6  
If the Research Study is funded by an external sponsor, I will 
not begin the Research Study until the contract/agreement has 
been approved by the appropriate university, hospital, or 
research institute official. 
Yes 
8.7  
Have you exported a copy of this submission to Word using the 
"Export to Word" button? Note that you will be unable to 
submit future revisions if this is not done. 
Yes 
8.8  
Have you uploaded the following documents, if applicable, to 
the attachments tab? Incomplete submissions will be returned 
without being reviewed. 
Letter(s) of 
Information and 
Consent 
Documentation 
9. Confirmation of Responsibility - Student 
# Question Answer 
9.1  Is this a student project? Yes 
9.2  
As the Student I have read the Tri-Council Policy Statement 2 
and Western University's Guidelines on Research Involving 
Human Subjects and agree to abide by the guidelines therein: 
http://uwo.ca/research/ethics/health_sciences/d_guidelines.html 
Yes 
9.3  
I will adhere to the Protocol and Letter(s) of Information as 
approved by the REB; 
Yes 
9.4  
I will notify the Principal Investigator as soon as possible if 
there are any changes or adverse/experiences, 
violations/deviations in regards to the Research Study. 
Yes 
Attachments 
Description File Name 
Version 
Date 
Letter of Information and Consent 
Thyroid Circulating Tumor REB 
v10.docx 
22/06/2013 
  103985 - Nichols.pdf 22/06/2013 
  
Thyroid Circulating Tumor REB v20 - 
with highlights.docx 
25/09/2013 
  
Thyroid Circulating Tumor REB 
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Appendix H: List of Abbreviations 
 
ASIR Age Standardized Incidence Rate 
AUS Atypia of Unknown Significance 
cfDNA Cell free DNA 
ctDNA Circulating Tumor DNA 
FNAB Fine Needle Aspirate Biopsy 
FLUS Follicular Lesion of Unknown Significance 
FN Follicular Neoplasm 
FTC Follicular Thyroid Cancer 
LHSC London Health Sciences Centre 
PTC Papillary Thyroid Cancer 
PCR Polymerase Chain Reaction 
SFN Suspicious for Follicular Neoplasm (or Hurthle Cell Neoplasm) 
TSH Thyroid Stimulating Hormone 
US Ultrasound 
US-FNAB Ultrasound guided Fine Needle Aspirate Biopsy 
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